WO2006073147A1 - 脂肪毒性の改善剤 - Google Patents
脂肪毒性の改善剤 Download PDFInfo
- Publication number
- WO2006073147A1 WO2006073147A1 PCT/JP2006/300008 JP2006300008W WO2006073147A1 WO 2006073147 A1 WO2006073147 A1 WO 2006073147A1 JP 2006300008 W JP2006300008 W JP 2006300008W WO 2006073147 A1 WO2006073147 A1 WO 2006073147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- fatty acid
- lipotoxicity
- spleen
- cells
- Prior art date
Links
- 231100000419 toxicity Toxicity 0.000 title abstract description 8
- 230000001988 toxicity Effects 0.000 title abstract description 8
- 230000000246 remedial effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 47
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000000512 lipotoxic effect Effects 0.000 claims description 46
- 210000000952 spleen Anatomy 0.000 claims description 40
- 230000003914 insulin secretion Effects 0.000 claims description 34
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 32
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 11
- 208000013824 Acidemia Diseases 0.000 claims description 8
- 208000010444 Acidosis Diseases 0.000 claims description 8
- 230000003820 β-cell dysfunction Effects 0.000 claims description 8
- 230000003393 splenic effect Effects 0.000 claims description 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 6
- 230000030833 cell death Effects 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- CYEDOLFRAIXARV-UHFFFAOYSA-N ethyl propyl carbonate Chemical compound CCCOC(=O)OCC CYEDOLFRAIXARV-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 70
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- 235000021314 Palmitic acid Nutrition 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 31
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 31
- 235000021588 free fatty acids Nutrition 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 12
- 239000005642 Oleic acid Substances 0.000 description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- -1 ethyl esters Chemical class 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 235000021319 Palmitoleic acid Nutrition 0.000 description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 210000003240 portal vein Anatomy 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229940122199 Insulin secretagogue Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000667 effect on insulin Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010014 adipocyte dysfunction Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- DTEMJWLYSQBXEL-UHFFFAOYSA-N ethyl icosa-2,4,6,8,10-pentaenoate Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC DTEMJWLYSQBXEL-UHFFFAOYSA-N 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- KYYWBEYKBLQSFW-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O KYYWBEYKBLQSFW-UHFFFAOYSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000022001 negative regulation of insulin secretion Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- the present invention relates to an agent for improving lipotoxicity.
- Adipocytes are specialized cells that can store large amounts of free fatty acids as neutral fat, and cells other than fat cells (non-adipocytes) cannot store large amounts of neutral fat. Yes. Adipocytes break down triglycerides continuously or in response to specific stimuli into diglycerol and free fatty acids. Free fatty acids are hemolysates that are insoluble in water, but when combined with albumin, they become nontoxic and soluble and are transported to the liver for use. When the fatty acid albumin complex enters the liver, the fatty acid is quickly taken into the liver and only albumin returns to the blood. In addition, free fatty acids generated by decomposition are re-esterified by the action of insulin. Thus, in a normal state, the free fatty acid concentration in plasma is kept within a certain range.
- Non-Patent Documents 1 to 3 When the non-adipocytes are spleen ⁇ cells, it is known that apoptosis and glucose-stimulated insulin secretion disorder occur due to lipotoxicity. Specifically, it has been reported that palmitic acid induces apoptosis, growth inhibition and glucose-stimulated insulin secretion deficiency in cultured spleen j8 cells, and stearic acid induces apoptosis of cultured spleen j8 cells. (For example, see Non-Patent Documents 1 to 3).
- spleen increases cellulose sensitivity in 8 cells due to glucose toxicity, insulin is over-secreted, spleen) 8 cells become exhausted, Stimulated insulin secretion decreases. It is also known that spleen j8 cells are reduced (for example, see Non-Patent Document 2).
- fatty acids such as palmitoleic acid (16 carbon atoms, 1 degree of unsaturation, ⁇ 7 series), oleic acid (18 carbon atoms, 1 degree of unsaturation, ⁇ 9 series) and linoleic acid (18 carbon atoms) It has been reported in experiments using rat or human cultured spleen ⁇ cells that the degree of unsaturation 2 and the ⁇ 6 system) has a preventive action against lipotoxicity and glucotoxicity.
- Non-Patent Document 1 In contrast to the lipotoxicity caused by palmitic acid (saturated fatty acid) in rat splenic Langernos islet cells, the addition of palmitoleic acid improved the apoptosis and growth inhibition of splenic j8 cells and the inhibition of glucose-stimulated insulin secretion. (For example, see Non-Patent Document 1).
- Palmitoleic acid has been developed in advance against the lipotoxicity of human and rat cultured spleen ⁇ -cells caused by normitic acid. It has been disclosed that the addition of oleic acid or linoleic acid suppresses apoptosis of spleen j8 cells (see, for example, Non-Patent Document 3).
- Non-Patent Document 4 shows experimental results using cultured cells for the prevention of lipotoxicity and sputum or glycotoxicity of several types of fatty acids, but there are reports that are contradictory, such as oleic acid. It's hard to say that the situation is always clear. In addition, there is no description of in vivo effects, and there is no description of improvement effects. There is no description of things that have both improvements.
- Thiazolidine derivatives have the function of protecting non-adipocytes by causing free fatty acids to accumulate in adipocytes, and biguanide drugs use sugars such as spleen ⁇ 8 cells damaged by lipotoxicity. It is known to normalize sputum. Nicotinamide and aminognidine have been shown to inhibit apoptosis caused by lipotoxicity as inhibitors of inducible nitric oxide synthase (iNOS). However, these drugs are known to have side effects. As described above, there is no clinically satisfactory drug that has an effect of improving lipotoxicity and thus sugar toxicity and has few side effects.
- Non-Patent Document 1 Medler, K. et al., Diabetes, 2001, 50 ⁇ , p.69-76
- Non-Patent Document 2 Medler, K. et al., Diabetes, 2003, 52 ⁇ , p.726-733
- Non-Patent Document 3 Eiteru, cable (Eitel, K.), bio-chemical and bio-physical Lisa ⁇ ⁇ Te co- ⁇ Yunike 1 ⁇ N'yonzu (Biochemical and Biophysical Research Communica tions) , 2002 years, 299 Certificates, p.853 -856
- Non-patent document 4 Busch, A. N., etc., Diabetes, 2002, 51 ⁇ , p.977-987
- An object of the present invention is to provide such a drug in a situation where there is no clinically satisfactory drug that has a preventive and ameliorating action on lipotoxicity, has few side effects, and is clinically satisfactory. There is.
- the present inventors have conducted extensive research to solve the above-mentioned problems. As a result, unsaturated fatty acids having 18 to 22 carbon atoms and 3 to 6 degrees of unsaturation and derivatives thereof are capable of preventing lipotoxicity. ⁇ The present invention was completed by finding that it has an improving action. That is, the present invention has the following features: (1) The number of carbons is 18 !, then 22 !, the deviation and the degree of unsaturation are 3 !, then 6! It is an agent for improving lipotoxicity, comprising a Japanese fatty acid or derivative thereof or a mixture thereof as an active ingredient.
- the unsaturated fatty acid is at least one selected from a-linolenic acid, icosapentanoic acid, docosahexaenoic acid, and derivatives thereof.
- the improving agent according to (6) above which is a derivative of icosapentaenoic acid ethyl ester and Z or docosahexaenoic acid ethyl ester of unsaturated fatty acid.
- the lipotoxicity-improving agent of the present invention comprising an unsaturated fatty acid having 18 to 22 carbon atoms and 3 to 6 carbon atoms or a derivative thereof as an active ingredient as described above has various causes, diseases, It is useful as an agent for preventing or improving lipotoxicity in pathological conditions.
- FIG. 1 shows the inhibitory (preventive) effect of the lipotoxicity-improving agent of the present invention on insulin secretion failure of spleen ⁇ -cells due to lipotoxicity, and protein when each group of Min6 cells is stimulated with glucose It is a graph which shows the amount of insulin secretion per lmg.
- FIG. 2 The effect of the lipotoxicity improving agent of the present invention on insulin secretion failure of spleen ⁇ cells due to lipotoxicity is shown.
- Min6 cells loaded with palmitic acid are supplemented with various fatty acids and stimulated with glucose. It is a graph which shows the insulin production per lmg protein when doing.
- FIG. 3 is a graph showing blood free fatty acid concentrations in mice of each group loaded with normitine
- FIG. 4 is a graph showing the amount of insulin secreted per 1 ⁇ g of DNA when splenic ⁇ cells isolated from each group of mice loaded with palmitic acid were stimulated with glucose.
- FIG. 5 is a graph showing the combined effect of a long-chain polyunsaturated fatty acid and an insulin secretagogue on insulin secretion failure of splenic ⁇ cells due to lipotoxicity.
- an unsaturated fatty acid having 18 to 22 carbon atoms and an unsaturated degree of 3 to 6 or a derivative thereof (hereinafter may be collectively referred to as a specific unsaturated fatty acid) is an effective component. It is an agent for improving lipotoxicity.
- the improving agent includes a prophylactic agent.
- unsaturated fatty acid derivatives include salts with inorganic bases such as sodium salts, salts with organic bases such as benzylamine salts, salts with basic amino acids, alkyl esters such as ethyl esters, and esters such as glycerides. Triglycerides or ethyl esters are preferable, and ethyl esters are more preferable.
- a preferred example of the specific unsaturated fatty acid is an ⁇ 3 fatty acid or a derivative thereof.
- Preferred examples of the unsaturated fatty acid include ⁇ -linolenic acid (hereinafter abbreviated as LA), icosapentanoic acid (hereinafter abbreviated as EPA), docosahexaenoic acid (hereinafter abbreviated as DHA), and the like. Derivative power of 1 or more selected.
- EPA is an unsaturated fatty acid with 20 carbon atoms and a degree of unsaturation of 5.
- PA is a cis-type linear unsaturated ⁇ 3 fatty acid with double bond positions of 5, 8, 11, 14, and 17.
- DHA is an unsaturated fatty acid with 22 carbon atoms and 6 degrees of unsaturation.
- DHA used in the present invention is a cis-type straight chain unsaturated ⁇ 3 fatty acid having double bond positions of 4, 7, 10, 13, 16, and 19.
- a LA is an unsaturated fatty acid having 18 carbon atoms and a degree of unsaturation of 3, and is a cis-type linear unsaturated ⁇ 3 fatty acid with 9, 12, and 15 double bonds.
- an improving agent containing, as an active ingredient, a derivative of the above unsaturated fatty acid containing ⁇ ethyl ester (hereinafter abbreviated as EPA— ⁇ ) and ⁇ or DHA ester (hereinafter abbreviated as D HA— ⁇ ).
- EPA— ⁇ ⁇ ethyl ester
- DHA— ⁇ DHA ester
- the present invention provides a lipotoxicity improving agent comprising the above-mentioned specific unsaturated fatty acid as an active ingredient.
- lipotoxicity refers to the non-existence of liver, heart, spleen, kidney, skeletal muscle, etc., if for some reason a large amount of free fatty acids are present continuously or repeatedly in plasma, particularly portal vein plasma. A fat cell is dysfunctional.
- lipotoxicity when non-adipocytes are spleen ⁇ cells include apoptosis of spleen j8 cells, inhibition of proliferation, and induction of dulcose-stimulated insulin secretion failure.
- blood glucose levels rise when dulcose-stimulated insulin secretion decreases in spleen j8 cells.
- fatty acids that cause lipotoxicity include, but are not limited to, force S, including palmitic acid, stearic acid, and oleic acid.
- an example of a specific embodiment of the present invention is an agent for improving lipotoxicity, wherein the lipotoxicity is splenic ⁇ -cell dysfunction.
- Spleen j8 cells are insulin-secreting cells in the islet of Langernons.
- Insulin is a rough endoplasmic reticulum of spleen ⁇ -cells that is synthesized as proinsulin, a biosynthetic precursor, which is converted into insulin, stored in spleen j8 cells, and released into the blood in response to secretory stimulation.
- Secretion is primarily facilitated by glucose.
- the main physiological action of insulin is blood glucose lowering action.
- 8 cell dysfunction includes insulin secretion failure, growth inhibition and cell death (necrosis, apoptosis).
- the present invention is specifically an agent for improving fat toxicity, wherein the spleen ⁇ -cell dysfunction is insulin secretion failure.
- the present invention is also a lipotoxicity-improving agent in which spleen
- Cell death in the present invention includes both necrosis and apoptosis.
- the lipotoxicity improving agent according to the present invention is specifically characterized by being administered to patients with hyperfree fatty acidemia.
- Hyperfree fatty acidemia refers to a condition in which a large amount of free fatty acid is present continuously or repeatedly in plasma, particularly portal vein plasma. Hyperfree fatty acidemia can cause non-adipocyte dysfunction, ie, lipotoxicity.
- the improving agent of the present invention contains at least one of the above-mentioned specific unsaturated fatty acids as an active ingredient, and may be a single product of the unsaturated fatty acid or a mixture thereof.
- the content of the unsaturated fatty acid that is an active ingredient of the improving agent of the present invention is not particularly defined, but is preferably 20% by weight or more, more preferably 50% by weight or more, and further preferably 85% by weight or more, based on the total weight of fatty acids. More preferably, it is 95% by weight or more, particularly preferably substantially free from other fatty acid components.
- ⁇ - ⁇ and ⁇ or DHA- ⁇ are more preferable as derivatives in which ⁇ 3 polyunsaturated fatty acids, particularly ⁇ and ⁇ or DHA are preferred.
- the unsaturated fatty acid used in the improving agent of the present invention can be prepared by a known method such as extraction and purification of natural products or chemical synthesis.
- the method of treating the unsaturated fatty acid thus obtained with esterification is known to those skilled in the art.
- a naturally occurring unsaturated fatty acid Specifically, sardine oil, squid oil, cod liver oil, mennosudeden oil, krill oil, dicin oil, saury oil, By treating mackerel oil etc. with known purification methods such as deoxidation, decolorization, deodorization, degumming, dewaxing, etc., if necessary, solvent fractionation method, urea addition method, molecular distillation method etc. It can be used as a mixture obtained by concentrating other fatty acids such as DH ⁇ to a predetermined amount.
- the improver of the present invention administers only the specific unsaturated fatty acid as an active ingredient, Alternatively, suitable carriers or media generally used for the unsaturated fatty acids, such as excipients, binders, lubricants, coloring agents, flavoring agents, if necessary, sterile water or vegetable oil, Harmless organic solvents or harmless solubilizers (eg, glycerin, propylene diol), emulsifiers, suspending agents (eg, Tween 80, gum arabic solution), isotonic agents, pH adjusters, stabilizers, soothing agents
- suitable carriers or media generally used for the unsaturated fatty acids such as excipients, binders, lubricants, coloring agents, flavoring agents, if necessary, sterile water or vegetable oil, Harmless organic solvents or harmless solubilizers (eg, glycerin, propylene diol), emulsifiers, suspending agents (eg, Tween 80, gum arabic solution), isot
- the improving agent of the present invention is an aqueous extract of red grape vine leaves or a flavonoid that is an active ingredient thereof, French pine pine peel extract or an active ingredient thereof as an active ingredient other than unsaturated fatty acids and derivatives thereof. May include Pycnogenol, Umadari extract, Hazel extract, etc. It may also contain ingredients to enhance the absorption of unsaturated fatty acids and their derivatives, such as lecithin! /.
- the improving agent of the present invention is a drug having an action of promoting insulin secretion of spleen ⁇ -cells, for example, sulfonylurea insulin secretion promoters such as tolptamide, glimepiride, daliclazide and darribenclamide, nateglinide gumitiglinide and the like It is desirable to use in combination with biguanide drugs such as the fast-acting insulin secretagogue and metformin-buformin.
- sulfonylurea insulin secretion promoters such as tolptamide, glimepiride, daliclazide and darribenclamide, nateglinide gumitiglinide and the like
- biguanide drugs such as the fast-acting insulin secretagogue and metformin-buformin.
- the combination includes any of a method of administering as a combination drug, a method of simultaneous administration as individual preparations, or a method of sequentially administering one after the other.
- Combined use is expected to not only enhance the lipotoxicity-improving effect, but also inhibit the progression of glucose tolerance to diabetes borderline and diabetes. In addition, it is expected to improve the patient's quality of life by reducing the dose, frequency and duration of both drugs, and reducing side effects.
- the dosage form of the improving agent of the present invention includes tablets, capsules, microcapsules, granules, fine granules, powders, liquid preparations for oral use, jellies, suppositories, syrups, inhalants, eye drops Oral, intravenous or intraarterial, inhalation, eye drops, in the form of a solid injection for use in emulsions, ointments, injections (emulsifying, suspending, non-aqueous) or emulsions or suspending Force to be administered to a patient regardless of rectal, vagina, or topical use.
- oral administration in capsules such as soft capsules or microcapsules is preferred.
- Injectable (emulsion, suspension, Non-aqueous) or intravenous or intraarterial administration in the form of a solid injection that is used in an emulsion or suspension at the time of use is preferred.
- the ameliorating agent of the present invention can be used for the prevention * improvement of lipotoxicity in various causes, diseases and pathologies.
- administration targets of the improving agent of the present invention include obese, overeating, lack of exercise, high fat diet, especially Western dietary people who mainly consume animal meat, hyperlipidemia, hyperglycemia, impaired glucose tolerance, Hyperinsulinemia, diabetes, liver failure, hepatic encephalopathy, cirrhosis, jaundice, ascites, hepatitis, knee inflammation, knee dysfunction, renal failure, nephrotic syndrome, nephritis, uremic disease, heart failure, cardiomyopathy, rhabdomyolysis Etc., and patients with high free fatty acidemia, especially persistent or repeated high free fatty acids in portal vein plasma, can be used to prevent or improve lipotoxicity.
- hyperlipidemic patients hypertriglyceridemia patients, postprandial high triglyceride plasma patients whose plasma triglyceride concentration increases repeatedly after meals, and hyperglycemia, impaired glucose tolerance, diabetic boundaries Prevention of lipotoxicity in people with diabetes and diabetes * It can be used suitably for improvement.
- the improving agent of the present invention has high free fatty acidemia, particularly saturated fatty acids such as palmitic acid and stearic acid in patients with high free fatty acids in portal vein plasma, and has a high oleic acid concentration.
- the composition ratio of saturated fatty acids such as palmitic acid and stearic acid in Z or free fatty acids or stearic acid or oleic acid is high, and can be used more suitably for patients. It can be done by making decisions or judging the status of improvement.
- the concentration of saturated fatty acids such as palmitic acid and stearic acid or oleic acid is high! Since the constituent ratio of saturated fatty acids such as acids or the constituent ratio of oleic acid is high, it can be more suitably used for patients.
- the dosage of the improving agent of the present invention is an amount sufficient to exert the intended action, but its dosage form, administration method, number of administrations per day, symptom level, body weight, The dosage can be adjusted according to age.
- EPA when administered orally as an improving agent, EPA is administered at 0.1 to 9 gZ days, preferably 0.5 to 6 gZ days, more preferably 1 to 3 gZ days.
- the entire amount may be administered as a single dose or divided into several doses as needed. However, it is preferable to administer several times, specifically about 3 times. When administered orally, it is administered within 60 minutes after meal, preferably immediately after meal. In the case of intravenous or intraarterial administration, it is preferable to administer 1 to 200 mg as EPA, preferably 5 to 100 mg, more preferably 10 to 50 mg.
- the entire dose may be administered once or divided into several doses. If necessary, it can be administered continuously for several hours to several days using an infusion pump or infusion pump.
- BSA urine serum albumin
- the cell culture supernatant of (1) is removed, washed twice with phosphate physiological saline buffer (hereinafter abbreviated as PBS (—)), 0.5% (vZv) fatty acid-free BSA and glucose 2.8 mM.
- PBS phosphate physiological saline buffer
- vZv fatty acid-free BSA
- glucose 2.8 mM.
- KRBH buffer Krebs-Ringer-Bicarbonate-Hepes buffer
- CO 5% CO at 37 ° C.
- the cells are then washed twice with PBS (—), incubated with KRBH buffer containing 0.5% (vZv) BSA and 20 mM glucose for 1 hour at 5% CO, 37 ° C, and the supernatant is washed with 20 mM
- the insulin concentration of the collected sampnore was measured with a Levis insulin measurement kit (manufactured by Shibayagi, purchased from Nakayama Shoji), and the protein concentration was measured with the Lowry method (BCA kit), and the amount of insulin per mg of protein was quantified. The results are shown in Figure 1.
- Min6 cells (1-1) Min6 cells were seeded at 1.5 ⁇ 10 5 per well in a 24-well plate in DMEM medium (Gibco) and incubated overnight at 37% at 5% CO.
- Min6 cells cultured in (1-1) above were incubated in D MEM medium (manufactured by Sigma) for 48 hours in the same manner as in (1-2) above without adding 0.4 mM palmitic acid ( Normal group), as in the control group (1-3) above, the cells were washed twice with PBS (-) and washed with DMEM medium (Sigma) in the absence of fatty acid at 5% CO, 37 ° C. Incubate for an additional 48 hours at
- the amount of insulin secretion in the 20 mM glucose-stimulated sample decreased from 5007 ng (normal group: 100%) to 2481 ng (control group: 49.6%).
- ⁇ or a 4278ng (85.4 0/0) in the EPA group was ⁇ in DHA group or 4073ng (81.4 0/0).
- mice Male mice (C57BLZ6J, 8 weeks old, purchased from CLEA Japan) were bred for 1 week with fish meal-free F1 feed (Funabashi Farm), then divided into 4 groups of 9-10 animals per group.
- mice were fasted for 16 hours on the 14th day and the final day, blood was collected from the orbital venous plexus, serum was separated, and blood free fatty acids were enzymatically analyzed (NEFA test ⁇ Koichi, Wako Pure Chemical Industries, Ltd.) Measured using The results are shown in Figure 3.
- collagenase-treated spleen force was isolated from Langerhans islet by density gradient method in RPM11640 medium (manufactured by Sigma) containing 10% (v / v) urine fetal serum (purchased from Iwai Kagaku) and 1% by weight penicillin streptomycin.
- Glucose stimulation according to the procedure described in Experimental Example 1-1 (2) after culturing at 5% CO, 37 ° C for 2 hours
- Insulin secretion ability was evaluated. The results are shown in Fig. 4.
- the islets of Langerhans were washed with PBS (-) and dissolved by shaking vigorously in 20 / zL TNE buffer (0.1M Tris-HCL, pH7.4, 2M NaCl, 10mM EDTA). Use as the reaction solution.
- Luminescent solution (1.2 i u L Hoechst 33258 (manufactured by Wako Pure Chemical Industries, Ltd.) is added to TNE buffer lm L) 100 L of this reaction solution is added to 20 L and at room temperature for at least 8 hours. After the reaction, measurement was performed at an excitation wavelength of 350 nm and a measurement wavelength of 450 nm.
- a standard curve was prepared by measuring in the same manner using thymus DNA (manufactured by Sigma), and the amount of DNA was determined. The amount of insulin per ⁇ g of DNA in Langernos Island was quantified.
- Fig. 3 shows the action of each fatty acid on blood free fatty acid, and the blood free fatty acid concentration increased with time in the palmitic acid group compared to the control group.
- EPA group and palmitic acid + EPA group changes in blood free fatty acid concentrations were similar to those in the control group.
- EPA alone has no effect on blood free fatty acid concentration, but has an inhibitory effect on plasma free fatty acid increase due to palmitic acid loading.
- FIG. 4 shows the results of the action on insulin secretion failure.
- mice according to Experimental Example 3 Male mice according to Experimental Example 3 (C57BLZ6J, 8 weeks old, purchased from CLEA Japan) After isolating and culturing Langernos Island from the spleen, according to Experimental Example 1, 0.4 mM palmitic acid-induced 20 mM glucose-stimulated insulin secretion 50 ⁇ M EPA alone (palmitic acid + EPA group), 5 mM tolptamide alone (palmitic acid + tolptamide group) and 50 ⁇ M EPA in combination with 5 mM tolptamide (palmitic acid + The effect of the combination group) was evaluated. In accordance with Experimental Example 3, the amount of insulin per DNAlng of Langerno and Suns was quantified. The results are shown in FIG.
- the amount of insulin secreted in the 20 mM glucose-stimulated sample was 1029 pg (100%) in the control group, but decreased to 572 pg (55.6%) in the palmitic acid group. It was 823 pg (80.0%) in the palmitic acid + EPA group, 673 pg (65.4%) in the palmitic acid + tolptamide group, and 928 pg (90.2%) in the palmitic acid + combination group. 30mM
- Insulin secretion in the KC1-stimulated sample was 583 pg (100%) in the control group, but decreased to 229 pg (39.3%) in the palmitic acid group. It was 422 pg (72.4%) in the palmitic acid + E PA group, 316 pg (54.2%) in the normitic acid + tolptamide group, and 688 pg (118. 0%) in the palmitic acid + combination group.
- Sterilized soft gelatin capsule (approx. 1 mL), and a composition containing 1000 mg of ethyl acetate and refined fish oil (900 mg of polyunsaturated fatty acid ethyl ester (including EPA—E465 mg, DHA—E375 mg)) and 4 mg of tocopherol Filled and then sealed.
- ethyl acetate and refined fish oil 900 mg of polyunsaturated fatty acid ethyl ester (including EPA—E465 mg, DHA—E375 mg)) and 4 mg of tocopherol Filled and then sealed.
- Echiru reduction and purified fish oil i.e. EPA-E90.6 wt%, Arakidon acid E Ji glycol ester 2.3 weight o / 0, O Kuta deca tetra E phosphate Echiruesuteru 2.2 weight o / 0, .omega. 3- Ikosatetoraen acid Echiruesuteru 0.7 weight
- the oil containing 0.2% by weight of tocopherol in the composition containing 2% is placed in the filling tank of the concentric double cylindrical automatic soft capsule machine, while the coating tank is 37.8% gelatin and glycerin. 9.4% by weight, D-sorbitol 5.7% by weight, purified water 47.2% by weight are mixed separately, and the coating liquid prepared separately is put into the machine.
- the coating liquid transfer speed is set to 2.3 gZ, and then 200 Hz vibration is applied to the lower part of the orifice to adjust the cooling medium liquid transfer speed. 3. lmg Spherical seamless microcapsules were obtained. Under a nitrogen gas atmosphere, each 410 mg of this microcapsule was divided into 0.2 mm thick laminated aluminum foil (moisture-proof cellophane + aluminum foil + polyethylene).
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006550887A JP4954714B2 (ja) | 2005-01-04 | 2006-01-04 | 脂肪毒性の改善剤 |
EP06702028.9A EP1834639B8 (en) | 2005-01-04 | 2006-01-04 | Remedial agent for fat toxicity |
CA2593768A CA2593768C (en) | 2005-01-04 | 2006-01-04 | Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity |
US12/431,668 US8697749B2 (en) | 2005-01-04 | 2009-04-28 | Lipotoxicity relieving agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-000168 | 2005-01-04 | ||
JP2005000168 | 2005-01-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/794,697 A-371-Of-International US20080200707A1 (en) | 2005-01-04 | 2006-01-04 | Lipotoxicity Relieving Agent |
US12/431,668 Division US8697749B2 (en) | 2005-01-04 | 2009-04-28 | Lipotoxicity relieving agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006073147A1 true WO2006073147A1 (ja) | 2006-07-13 |
Family
ID=36647623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/300008 WO2006073147A1 (ja) | 2005-01-04 | 2006-01-04 | 脂肪毒性の改善剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8697749B2 (ja) |
EP (1) | EP1834639B8 (ja) |
JP (1) | JP4954714B2 (ja) |
CA (1) | CA2593768C (ja) |
WO (1) | WO2006073147A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087938A1 (ja) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
WO2009142242A1 (ja) * | 2008-05-20 | 2009-11-26 | 持田製薬株式会社 | ハイリスク患者の心血管イベント予防用組成物 |
WO2009151094A1 (ja) * | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2334295T3 (pl) | 2008-09-02 | 2017-12-29 | Amarin Pharmaceuticals Ltd | Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania |
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
EP3797591A1 (en) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
JP5934102B2 (ja) | 2009-10-30 | 2016-06-15 | レトロトップ、 インコーポレイテッドRetrotope, Inc. | Pufa誘導体による酸化ストレス障害の緩和 |
NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
JP6106158B2 (ja) | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドRetrotope, Inc. | 酸化的網膜疾患 |
EP3730135A1 (en) | 2011-04-26 | 2020-10-28 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
KR102014526B1 (ko) * | 2011-04-26 | 2019-08-26 | 레트로토프 인코포레이티드 | Pufa 산화와 관련된 장애 |
EP2701695B1 (en) | 2011-04-26 | 2019-04-03 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
HUE053111T2 (hu) | 2012-06-29 | 2021-06-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával |
CN104797249A (zh) * | 2012-09-28 | 2015-07-22 | 持田制药株式会社 | 用于减少新发糖尿病的组合物 |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
EP4107163A4 (en) | 2020-02-21 | 2024-06-19 | Retrotope, Inc. | PROCESS FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0408006A (pt) * | 2003-03-05 | 2006-02-14 | Solvay Pharm Gmbh | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos |
-
2006
- 2006-01-04 WO PCT/JP2006/300008 patent/WO2006073147A1/ja active Application Filing
- 2006-01-04 CA CA2593768A patent/CA2593768C/en not_active Expired - Fee Related
- 2006-01-04 EP EP06702028.9A patent/EP1834639B8/en not_active Not-in-force
- 2006-01-04 JP JP2006550887A patent/JP4954714B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-28 US US12/431,668 patent/US8697749B2/en active Active
Non-Patent Citations (7)
Title |
---|
"free fatty acid, lipotoxicity, obesity", 5., 2003, pages 24 - 29, XP002999564 * |
"Lipid disorder and lipotoxicity in diabetes mellitus", THE CELL, vol. 33, no. 8, 2001, pages 302 - 305, XP002999563 * |
ETO K. ET AL.: "Genetic Manipulations of Fatty Acid Metabolism in beta-Cells Are Associated With Dysregulated Insulin Secretion", DIABETES, vol. 51, no. 3, 2002, pages 414 - 420, XP002999562 * |
ITOH Y. ET AL.: "Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40", NATURE, vol. 422, no. 6928, 2003, pages 173 - 176, XP002903889 * |
OPARA E. C. ET AL.: "Characterization of the Isulinotropic Potency of Polyunsaturated Fatty Acids", ENDOCRINOLOGY, vol. 130, no. 2, 1992, pages 657 - 662, XP002999561 * |
See also references of EP1834639A4 * |
WOODMAN R. J. ET AL.: "Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 76, no. 5, 2002, pages 1007 - 1015, XP002999559 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087938A1 (ja) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
JP5421126B2 (ja) * | 2008-01-10 | 2014-02-19 | 武田薬品工業株式会社 | カプセル製剤 |
WO2009142242A1 (ja) * | 2008-05-20 | 2009-11-26 | 持田製薬株式会社 | ハイリスク患者の心血管イベント予防用組成物 |
JPWO2009142242A1 (ja) * | 2008-05-20 | 2011-09-29 | 持田製薬株式会社 | ハイリスク患者の心血管イベント予防用組成物 |
WO2009151094A1 (ja) * | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
Also Published As
Publication number | Publication date |
---|---|
EP1834639A4 (en) | 2009-03-25 |
CA2593768A1 (en) | 2006-07-13 |
EP1834639A1 (en) | 2007-09-19 |
EP1834639B8 (en) | 2016-12-07 |
US20090209644A1 (en) | 2009-08-20 |
JP4954714B2 (ja) | 2012-06-20 |
EP1834639B1 (en) | 2016-07-27 |
US8697749B2 (en) | 2014-04-15 |
JPWO2006073147A1 (ja) | 2008-06-12 |
CA2593768C (en) | 2014-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006073147A1 (ja) | 脂肪毒性の改善剤 | |
US20080200707A1 (en) | Lipotoxicity Relieving Agent | |
US11406602B2 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof | |
US4407821A (en) | Lipidic compositions for use in dietetics, reanimation and therapeutics | |
EP2638903A1 (en) | Suppressor for increase in blood glucose level | |
WO2006017627A2 (en) | Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance | |
SK14502003A3 (en) | Coenzyme Q and eicosapentaenoic acid | |
JPH06157303A (ja) | 脂肪酸治療 | |
US20120171285A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract | |
EP2682116B1 (en) | Metabolic syndrome ameliorating agent | |
KR20010079724A (ko) | 항 비만 및 내장축적지방 저감화기능을 보유하는 물질, 및그 용도 | |
Pavlisova et al. | Chronic n-3 fatty acid intake enhances insulin response to oral glucose and elevates GLP-1 in high-fat diet-fed obese mice | |
US20050222259A1 (en) | Methods of activating PPAR-alpha nuclear receptors in mammals | |
JP2020503388A (ja) | 悪液質を予防及び/又は処置するためのオメガ−3脂肪酸組成物 | |
JPH04244023A (ja) | ω6系不飽和脂肪酸含有薬剤 | |
JP3917825B2 (ja) | 血管新生抑制剤 | |
WO2005110393A1 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
JP2022150493A (ja) | 血中中鎖脂肪酸濃度の上昇方法、血中中鎖脂肪酸濃度上昇剤、医薬組成物、食品組成物 | |
Эргашева et al. | OMEGA-3 AND BIOCHEMICAL PROCESSES OF INFLAMMATION IN THE BODY | |
EP2090176A1 (en) | Postprandial hyperglycemia-improving agent | |
WO2013138411A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REEP | Request for entry into the european phase |
Ref document number: 2006702028 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006702028 Country of ref document: EP Ref document number: 2593768 Country of ref document: CA Ref document number: 2006550887 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006702028 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794697 Country of ref document: US |